Medications

Osteoarthritis is characterized by persistent inflammatory signaling, oxidative stress, chondrocyte dysfunction, and extracellular-matrix degradation

The infrapatellar fat pad (IPFP) is a crucial mediator in knee osteoarthritis (OA), but the mechanisms of its pathogenic signaling remain elusive

Osteoarthritis (OA) is a degenerative joint disease, for which effective disease-modifying therapies remain lacking

There is a critical need to understand the mechanisms that govern structural progression in osteoarthritis

Tongbi Lingding (TBLD) has demonstrated therapeutic effects in early- and mid-stage osteoarthritis (OA), but its active components and underlying mechanisms remain unclear

This study investigates the therapeutic potential of the synthetic cannabinoid WIN55,212-2 (WIN55) in temporomandibular joint osteoarthritis (TMJOA), focusing on its capacity to...

Review of OA drug delivery: exosomes, microparticles, nanoparticles, and hydrogels as carriers targeting articular chondrocytes and joint tissue; synthesis of nanoscale approaches to reducing cartilage degeneration.

Gut microbial fermentation transforms epimedium polysaccharides into short-chain fatty acids that deliver substantially enhanced chondroprotective activity; links the gut-joint axis to a traditional herbal compound.

The treatment of early-stage osteoarthritis (OA) remains clinically challenging, characterized by articular cartilage inflammation, cartilage damage and subchondral bone loss

Reviews 11 DMOAD candidates including lorecivivint, sprifermin, UBX0101, TPX-100, GLPG1972, lutikizumab; none approved as of 2024.

Reviews anabolic, anti-catabolic, and anti-inflammatory DMOAD strategies; identifies cartilage matrix as the correct therapeutic target.

Hyaluronic acid injections improve pain and function in knee OA; effect size modest and duration variable; works best in early OA with preserved cartilage.

MACI at minimum 10-year follow-up: significant durable improvement in patient-reported outcomes, satisfactory defect fill on MRI, low reoperation rate.

Vosoritide, a C-type natriuretic peptide analogue, approved for achondroplasia in children; increases annual height velocity.

Review of why intra-articular carriers fail the translation step: clearance, penetration, and retention are the three unsolved problems.

Preclinical: vestitol reduces ferroptosis features and OA progression via GSK3B/Nrf2/GPX4.

The repair of osteochondral defects is challenging due to differing regenerative capacities of bone and cartilage, a challenge that is often exacerbated by chronic inflammation

Preclinical: dietary polyphenol chlorogenic acid limits OA progression by activating Nrf2/HO-1 and suppressing ferroptotic cartilage loss.

Introduction: The clinical translation of biomaterial-based strategies for ear reconstruction remains limited by several challenges, including scaffold design, selection of an o...

The Notch signaling pathway is pivotal in joint homeostasis and the pathogenesis of osteoarthritis (OA)

Osteoarthritis (OA) is a major joint disorder characterized by cartilage matrix degradation and inflammatory responses

In vitro: hydroxysafflor yellow A limits oxidative lipid damage and calcification changes in endplate chondrocytes.

Osteoarthritis is a whole-joint disease involving articular cartilage, synovium, subchondral bone, fat pad, meniscus, blood vessels, and sensory nerves

Articular cartilage exists under hypoxic conditions, where hypoxia-inducible factor (HIF)-1α plays a critical role in maintaining its homeostasis

Post-traumatic osteoarthritis (PTOA) is a progressive joint disease characterised by cartilage degeneration and subchondral bone remodelling, in which persistent oxidative stres...

Cartilage fibrosis contributes to extracellular matrix remodelling and structural deterioration during osteoarthritis (OA) progression; however, the molecular regulators involve...

Osteoarthritis (OA) is characterized by progressive glycosaminoglycan (GAG) depletion caused by insufficient matrix replenishment and excessive proteoglycan catabolism

Osteoarthritis (OA) is a leading cause of disability worldwide, characterized by progressive joint degeneration driven by extracellular matrix (ECM) breakdown, chondrocyte apopt...

Osteoarthritis (OA) involves progressive cartilage breakdown

Review of how metformin protects chondrocytes through AMPK/SIRT1-driven autophagy and NF-kB suppression; positions a widely available drug as a candidate for OA intervention.

Preclinical hydrogel releasing hydrogen from magnesium, proposed as an OA therapy.

Nanoparticles coated with chondrocyte membrane homing peptide deliver tetrahedral framework nucleic acid (tFNA) to OA joints, polarising macrophages and protecting chondrocytes by rebalancing the cartilage-synovium inflammatory axis. Biomimetic targeting using the cell's own surface as camouflage.

Nanoparticles delivering Salvianolic acid B restore mitochondrial function in chondrocytes by activating PINK1/Parkin-mediated mitophagy; preclinical OA model.

Non-coding RNAs (ncRNAs) play a role in the pathogenesis of osteoarthritis (OA) by regulating gene expression related to inflammation, chondrocyte apoptosis, and extracellular m...

Cartilage degeneration in osteoarthritis (OA) is closely linked to ferroptosis-driven chondrocyte loss and extracellular matrix (ECM) degradation, yet effective therapeutic stra...

Chondrocyte hypertrophy is a key hallmark of osteoarthritis (OA) that drives a multitude of whole-joint disease processes

Decellularized extracellular matrix (dECM) particle-based hydrogels hold promise for cartilage repair

Osteoarthritis (OA) is increasingly recognized as a mechanically driven whole-joint disease in which abnormal mechanotransduction initiates a cascade of mitochondrial dysfunctio...

Current clinical management of osteoarthritis (OA) follows a stepwise, symptom-oriented approach that provides analgesia but exhibits limited disease-modifying efficacy

Ferroptosis is closely associated with the pathogenesis of osteoarthritis (OA), though the underlying molecular mechanisms remain unclear

Osteoarthritis (OA) is a prevalent degenerative joint disorder characterized by progressive cartilage destruction, chronic inflammation, pain, and functional impairment

The pathogenesis of osteoarthritis (OA) involves the degradation of the extracellular matrix (ECM) of cartilage, which is mainly mediated by matrix metalloproteinases (MMPs)

Idiopathic short stature (ISS) remains a clinically heterogeneous diagnosis in which impaired linear growth is often defined by exclusion rather than by mechanism

Osteoarthritis (OA) is a progressive joint disease characterized by cartilage degeneration, chronic low-grade inflammation, and disruption of tissue homeostasis

Cell-cell interactions play a critical role in regulating chondrocyte functions and cell fate

The limited intrinsic repair capacity of articular cartilage impairs tissue regeneration in osteoarthritis (OA)

Osteoarthritis (OA) is a chronic degenerative joint disorder characterized by articular cartilage deterioration, synovial inflammation, and progressive loss of joint function

Intervertebral disc degeneration (IVDD) is a leading global cause of chronic pain and functional impairment

Articular cartilage injury is a common clinical condition in orthopedics

BackgroundArticular cartilage and the inner (white) zone of the knee meniscus are characterized by minimal vascularity, a dense extracellular matrix (ECM), and cellular metaboli...

Systematic review of pharmacological and biological strategies to extend cartilage graft viability, covering growth factors, cryoprotectants, anti-apoptotic agents, and immunomodulators; translational synthesis relevant to reconstructive and repair applications.

Osteoarthritis (OA) is a common degenerative joint disease characterized by progressive cartilage degeneration

Oxidative stress is closely involved in osteoarthritis (OA), but the cell-type-specific oxidative stress landscape and related regulatory molecules in human cartilage remain inc...

The avascular and alymphatic nature of articular cartilage severely limits its intrinsic repair capacity

Osteoarthritis (OA) lacks approved disease-modifying therapies

Osteoarthritis (OA) is a progressive degenerative joint disorder characterized by cartilage breakdown, chronic inflammation, and impaired tissue homeostasis, representing a majo...

Osteoarthritis (OA) progression is driven by inflammatory mediators and immune dysregulation within the joint

Lack of intrinsic healing potential in cartilage, accompanied by accelerated inflammation and oxidative stress, creates a major clinical challenge for effective treatment of ost...

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease marked by persistent synovial inflammation, autoantibody production, cartilage damage, and bone erosion

Chronic inflammation and elevated reactive oxygen species (ROS) are pivotal drivers of osteoarthritis (OA), demanding integrated, pathology-adaptive strategies

Osteoarthritis (OA) progression is fueled by a self-perpetuating cycle of synovitis and cartilage degradation

Osteoarthritis (OA) is a chronic degenerative joint disorder characterized primarily by cartilage degradation and extensive inflammation

Extracellular matrix (ECM) dysregulation plays a significant role in the development of intervertebral disc disease (IVDD)

Diisononyl cyclohexane-1,2-dicarboxylate (DINCH), a widely used plasticizer substitute, has been widely detected in human populations and has emerged as a new environmental poll...

Articular cartilage homeostasis relies on chondrocytes to maintain extracellular matrix (ECM) integrity, with fluid shear stress (FSS) emerging as a critical regulator of chondr...

Osteoarthritis (OA) is characterized by progressive extracellular matrix (ECM) degradation, chondrocyte apoptosis, and hypertrophic differentiation, yet the molecular basis unde...

Articular cartilage defects present a significant clinical challenge due to the tissue's limited self-repair capacity

Osteoarthritis (OA) is the most prevalent degenerative joint disease and a leading cause of chronic pain and disability worldwide, particularly among aging populations

The development of targeted nanotherapeutics capable of restoring chondrocyte homeostasis represents a major challenge in osteoarthritis (OA) treatment

The limited regenerative capacity of injured meniscal tissue necessitates the development of advanced tissue-engineered alternatives

Osteoarthritis (OA) is a chronic degenerative joint disease characterized predominantly by articular cartilage degeneration, synovial inflammation, subchondral bone remodeling, ...

To investigate the protective effect of extracorporeal shock wave therapy (ESWT) on knee osteoarthritis (KOA) and clarify its molecular mechanism, focusing on focal adhesion sig...

Osteoarthritis (OA), a degenerative joint disease imposing a significant global disease burden, exhibits pathological mechanisms far more complex than mere "cartilage wear"

Non-coding RNAs (ncRNAs) have emerged as critical regulators of osteoarthritis (OA) pathogenesis by modulating gene expression at the epigenetic, transcriptional, and post-trans...

Osteoarthritis (OA) is a common chronic degenerative joint disease characterized by progressive cartilage destruction, synovial inflammation, subchondral bone remodeling, and fu...

Osteoarthritis (OA), one of the most common chronic joint diseases, is characterised by cartilage imbalance and disruption of the cartilage extracellular matrix

Osteoarthritis (OA) is a prevalent and debilitating joint disease driven by progressive cartilage degradation, mitochondrial dysfunction, and chronic inflammation

Osteoarthritis (OA) is progressively documented as a whole-joint disorder in which oxidative stress, iron dysregulation and intercellular communication together drive progressiv...

Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide and a leading cause of pain, disability, and reduced quality of life, with pronounced sex-specific...

The use of articular chondrocytes for cartilage repair is constrained by donor-site morbidity, poor proliferation, and difficulties to maintain a stable phenotype

Senolytics (dasatinib plus quercetin, navitoclax) and senomorphics (rapamycin) under review as pharmacological interventions for OA via chondrocyte senescence clearance.

The extracellular matrix (ECM) is composed of different networks with unique functional and structural characteristics that are formed by specific macromolecular suprastructures...

Intra-articular DMOAD trials 2025 update; sprifermin (FGF-18) showed cartilage thickness increase but not pain reduction; lorecivivint (Wnt/CLK2 inhibitor) in phase 3.

Editorial assessment: no approved DMOAD as of 2025; structural endpoints and patient-reported outcomes remain misaligned across trials.

ACI showed sustained clinical improvement at long-term follow-up for focal chondral defects; MACI is the current US-approved product (Carticel phased out 2017).